1. Home
  2. IKNA

IKNA

Ikena Oncology Inc.

Logo Ikena Oncology Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-22-2024 3:31pm EST

$
-
.
-
-
-
$
-
.
-
-
-
.
-
-
%

Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.

Founded: 2016 Country:
United States
United States
Employees: N/A City: BOSTON
Market Cap: 61.3M IPO Year: 2021
Target Price: $10.67 AVG Volume (30 days): 433.9K
Analyst Decision: Strong Buy Number of Analysts: 3
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -1.63 EPS Growth: N/A
52 Week Low/High: $1.02 - $7.64 Next Earning Date: 05-13-2024
Revenue: $9,160,000 Revenue Growth: -41.35%
Revenue Growth (this year): -22.05% Revenue Growth (next year): 21.43%

Share on Social Networks: